

**CARDIO3 BIOSCIENCES TO HOST INVESTOR & ANALYST DAY IN NEW YORK
ON FRIDAY, JANUARY 30, 2015**

*Company Management and Scientific Experts in Cardiac Cell Therapy and Immuno-Oncology
to Discuss Science and Portfolio Drug Candidates*

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery and development of cell therapies, will host an Investor & Analyst Day on **Friday 30th January 2015** in **New York City**.

The event will bring together scientific experts and key opinion leaders in cardiology and immuno-oncology from the **Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine (MD, USA)**, the **Institute of Cancer Sciences, University of Manchester (UK)**, the **Mayo Clinic (MN, USA)**, **Dartmouth College (NH, USA)** and the **Dana-Farber Cancer Institute (MA, USA)**. Together with members of Cardio3 BioSciences' management team, they will provide a comprehensive overview of the company's current pipeline in cardiac cell therapy, cardiac medical devices and immuno-oncology, substantiated with pre-clinical and clinical data.

The objective of this event is to present the Company's current pipeline of products, development perspectives for the coming years, and near and long-term business strategy. This event will also enable members of the financial community to meet with Cardio3 BioSciences' management and key opinion leaders for in-depth discussion and understanding of the Company and its strategy.

Details of the Investor & Analyst Day:

- **Date:** Friday January 30, 2015
- **Time:** 7:30 AM - 12:15 PM ET
- **Location:** The New York Palace, 455 Madison Avenue, New York

Attendance at The Cardio3 BioSciences Analyst Day is by invitation only.

To request an invitation for the event, please contact Courtney Dugan or Taylor Donovan of The Ruth Group at cdugan@theruthgroup.com / tdonovan@theruthgroup.com or +1 646-536-7024 / 7017.

***** END *****

For more information, please contact:

Cardio3 BioSciences

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

For Europe: Consilium Strategic Communications

Amber Bielecka, Chris Welsh, Laura Thornton

For France: NewCap

Pierre Laurent / Antoine Denry

www.c3bs.com

Tel. : +32 10 39 41 00

jgrade@c3bs.com

Tel : +44 (0)20 3709 5700

cardio3@consilium-comms.com

Tel: + 33(0)1.44.71.94.94

cardio3@newcap.fr

For the U.S: The Ruth Group

Lee Roth (Investors), Kirsten Thomas (Media)

Tel: +1 646 536 7012 / 7014

lroth@theruthgroup.comkthomas@theruthgroup.comTo subscribe to Cardio3 BioSciences' newsletter, visit www.c3bs.com. Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).**About Cardio3 BioSciences**

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of cell therapies. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_{ez}[®], the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.